aAP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire bUniversity Paris-Sud, UMR-S 785 cInserm, Unité 785, Villejuif dAP-HP, HôpitalBicêtre, Pharmacie Clinique eAP-HP, Hôpital Bicêtre, Service de Médecine Interne, Immunologie et Maladies Infectieuses, Le Kremlin Bicêtre fAP-HP Hôpital Paul Brousse, Service de Virologie gAP-HP, Hôpital Paul Brousse, Service Anatomie Pathologique hAP-HP, Hôpital Paul Brousse, Pharmacie Clinique, Villejuif iAP-HP, GH Xavier Bichat-Claude Bernard, Laboratoire de Toxicologie et Pharmacocinétique jUniversité Paris, Paris kHepatinov, Villejuif, France.
AIDS. 2013 Oct 23;27(16):2655-7. doi: 10.1097/01.aids.0000432539.77711.f4.
We report, for the first time, the outcome of anti-hepatitis C virus (HCV) triple therapy with telaprevir in an HIV/HCV co-infected transplanted patient. After liver transplantation, the patient experienced a severe HCV recurrence with fibrosing cholestatic hepatitis, and anti-HCV therapy with pegylated interferon alpha 2a, ribavirin and telaprevir was initiated. A sustained virological response was achieved after 48 weeks of anti-HCV therapy. Drug-drug interactions between antiretroviral therapy, immunosuppressive agents and anti-HCV therapy could be managed.
我们首次报告了替拉瑞韦在 HIV/HCV 合并感染移植患者中进行抗丙型肝炎病毒（HCV）三联治疗的结果。肝移植后，该患者发生严重的 HCV 复发，伴有纤维性胆汁性肝炎，并开始接受聚乙二醇干扰素α2a、利巴韦林和替拉瑞韦联合抗 HCV 治疗。在抗 HCV 治疗 48 周后达到持续病毒学应答。抗逆转录病毒治疗、免疫抑制剂和抗 HCV 治疗之间的药物相互作用可以得到管理。
